NMS Group, Italy's largest oncology-focused R&D company, employs over 400 individuals, with more than half in advanced research and manufacturing roles. Its kinase inhibitor and antibody-conjugate platforms drive innovation, establishing NMS as a global leader in personalized therapies. Notably, NMS discovered entrectinib, a targeted kinase inhibitor for NTRK1/2/3 and ROS1-dependent tumors, now commercialized globally through Roche.
The Group includes three subsidiaries: NMS S.r.l., focused on FIC/BIC cancer drug development with a dozen active projects; Accelera, a preclinical CRO; and NerPharMa, which manufactures APIs and drug products for clinical and commercial use.
Company Details
- Employees
- 112
- Address
- Viale Pasteur, 10, Nerviano,(Mi) 20014,italy
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- nmsgroup.it
- Keywords
- Discovery by Nerviano Medical Sciences, Preclinical research by Accelera, Clinical development starting from First-Time-In-Man by Clioss, From formulation to production of the active principle by Nerpharma, Turn-key oncological treatment from discovery to production.
- HQ
- Nerviano, (MI)
Nms Group Questions
Nms Group's website is nmsgroup.it
Nms Group's LinkedIn profile is https://it.linkedin.com/company/nms-group
Nms Group has
112 employees.
View email and phone details for 112
employees at Nms Group.
Nms Group's industry is
Research Services
Nms Group's categories are Research Services
